S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
Log in

Opko Health Stock Price, Forecast & Analysis (NASDAQ:OPK)

$1.43
-0.03 (-2.05 %)
(As of 11/12/2019 04:00 PM ET)
Today's Range
$1.43
Now: $1.43
$1.48
50-Day Range
$1.42
MA: $1.85
$2.15
52-Week Range
$1.33
Now: $1.43
$3.93
Volume3.74 million shs
Average Volume4.78 million shs
Market Capitalization$951.81 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$990.30 million
Book Value$3.06 per share

Profitability

Net Income$-153,040,000.00

Miscellaneous

Employees5,690
Market Cap$951.81 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.


Opko Health (NASDAQ:OPK) Frequently Asked Questions

What is Opko Health's stock symbol?

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

How were Opko Health's earnings last quarter?

Opko Health Inc. (NASDAQ:OPK) announced its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.02. The biotechnology company had revenue of $228.80 million for the quarter, compared to analysts' expectations of $225.40 million. Opko Health had a negative net margin of 30.98% and a negative return on equity of 14.42%. The firm's quarterly revenue was down 8.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) earnings per share. View Opko Health's Earnings History.

When is Opko Health's next earnings date?

Opko Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Opko Health.

What price target have analysts set for OPK?

1 Wall Street analysts have issued 12 month price objectives for Opko Health's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Opko Health's share price to reach $4.00 in the next year. This suggests a possible upside of 179.7% from the stock's current price. View Analyst Price Targets for Opko Health.

What is the consensus analysts' recommendation for Opko Health?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.

What are Wall Street analysts saying about Opko Health stock?

Here are some recent quotes from research analysts about Opko Health stock:
  • 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time." (10/18/2019)
  • 2. Barrington Research analysts commented, "We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline." (9/12/2019)

Has Opko Health been receiving favorable news coverage?

News headlines about OPK stock have trended very negative recently, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Opko Health earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Opko Health.

Who are some of Opko Health's key competitors?

What other stocks do shareholders of Opko Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), bluebird bio (BLUE), Micron Technology (MU), Gray Television (GTN), Allergan (AGN), Gilead Sciences (GILD), Bausch Health Companies (BHC), AT&T (T), NVIDIA (NVDA) and Novavax (NVAX).

Who are Opko Health's key executives?

Opko Health's management team includes the folowing people:
  • Dr. Phillip Frost, Chairman & CEO (Age 83)
  • Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
  • Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
  • Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)

Who are Opko Health's major shareholders?

Opko Health's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include RK Asset Management LLC (0.20%), California Public Employees Retirement System (0.11%), Rhumbline Advisers (0.09%), Mackay Shields LLC (0.07%), Commonwealth Equity Services LLC (0.07%) and Gabelli Funds LLC (0.03%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.

Which major investors are selling Opko Health stock?

OPK stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC and SG Americas Securities LLC. View Insider Buying and Selling for Opko Health.

Which major investors are buying Opko Health stock?

OPK stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Gamco Investors INC. ET AL, Rhumbline Advisers, RK Asset Management LLC, Mackay Shields LLC, Alpha Cubed Investments LLC and Commonwealth Equity Services LLC. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.

How do I buy shares of Opko Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Opko Health's stock price today?

One share of OPK stock can currently be purchased for approximately $1.43.

How big of a company is Opko Health?

Opko Health has a market capitalization of $951.81 million and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.View Additional Information About Opko Health.

What is Opko Health's official website?

The official website for Opko Health is http://www.opko.com/.

How can I contact Opko Health?

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at mmi[email protected]


MarketBeat Community Rating for Opko Health (NASDAQ OPK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  419 (Vote Outperform)
Underperform Votes:  399 (Vote Underperform)
Total Votes:  818
MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel